Research programme: chimeric antigen receptor T cell therapeutics - Shanghai Youkadi Biomedical Technology
Latest Information Update: 02 Mar 2017
At a glance
- Originator Shanghai Youkadi Biomedical Technology
- Developer Shanghai Youkadi Biomedical Technology; Soochow University
- Class CAR-T cell therapies
- Mechanism of Action T-cell receptor antigen modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute lymphoblastic leukaemia
Most Recent Events
- 01 Aug 2016 Phase-I clinical trials in Acute lymphoblastic leukaemia (In adolescents, In children, In adults) in China (unspecified route) (NCT03064269)